RAS pathway influences the number of melanocytic nevi in cardiofaciocutaneous and Costello syndromes - 14/04/20
Doi : 10.1016/j.jaad.2020.01.038
Maija Kiuru, MD, PhD a, b, ⁎ 
, Jennifer Urban, MD a, Guannan Zhu, MD, PhD a, c, Iryna Rybak, BA a, Jessica R. Terrell, BA a, Lihong Qi, MS, PhD d, John D. McPherson, PhD e, Ashfaq A. Marghoob, MD f, Katherine A. Rauen, MD, PhD g
, Jennifer Urban, MD a, Guannan Zhu, MD, PhD a, c, Iryna Rybak, BA a, Jessica R. Terrell, BA a, Lihong Qi, MS, PhD d, John D. McPherson, PhD e, Ashfaq A. Marghoob, MD f, Katherine A. Rauen, MD, PhD g a Department of Dermatology, University of California, Davis, Sacramento
b Department of Pathology and Laboratory Medicine, University of California, Davis, Sacramento
c Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China
d Department of Public Health Sciences, University of California, Davis, Sacramento
e Department of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento
f Dermatology Service, Memorial Sloan Kettering Cancer Center, New York
g Department of Pediatrics, University of California, Davis, Sacramento
∗Correspondence to: Maija Kiuru, MD, PhD, Department of Dermatology, University of California, Davis, 3301 C St, Ste 1450, Sacramento, CA 95816Department of DermatologyUniversity of California, Davis3301 C St, Ste 1450SacramentoCA95816
| Funding sources: Supported by the Dermatology Foundation, through a Career Development Award in Dermatopathology (to Dr Kiuru), and the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, through grant no. K23AR074530 (to Dr Kiuru) and grant no. R01AR062165 (to Dr Rauen). |
|
| Conflicts of interest: None disclosed. |
|
| Part of this project was presented at the Society of Investigative Dermatology Annual Meeting, Chicago, IL, May 8-11, 2019. |
|
| IRB approval status: Reviewed and approved by University of California Davis IRB (960347). |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 82 - N° 5
P. 1091-1093 - mai 2020 Retour au numéro
Article précédent
- Bullous pemphigoid: Rituximab to the rescue?
- Warren R. Heymann
- High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa
- Mondana H. Ghias, Andrew D. Johnston, Allison J. Kutner, Robert G. Micheletti, H. Dean Hosgood, Steven R. Cohen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?